The Clinical Study of Individualized Induction Therapy for Non-elderly Patients With Acute Myeloid Leukemia and Adverse Risk Features Guided by Rapid Screening With FISH and NGS
Latest Information Update: 07 Feb 2023
Price :
$35 *
At a glance
- Drugs Decitabine (Primary) ; Venetoclax (Primary) ; Azacitidine; Cytarabine; Idarubicin; Sorafenib
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 13 Dec 2022 Status changed from recruiting to active, no longer recruiting, according to results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Updated safety and efficacy results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 14 Dec 2021 Interim Results (as of July 2021, n=19)presented at the 63rd American Society of Hematology Annual Meeting and Exposition